Similar articles

• Intravenous cyclophosphamide in patients with chronic systemic inflammatory diseases: morbidity and mortality.

  Gøransson LG, Brodin C, Ogreid P, Janssen EA, Romundstad PR, Vatten L, Wildhagen K, Kjellevold K, Omdal R. Gøransson LG, et al. Scand J Rheumatol. 2008 Mar-Apr;37(2):130-4. doi: 10.1080/03009740701687234. Scand J Rheumatol. 2008. PMID: 18415771
• Incidence of Cyclophosphamide-induced Urotoxicity and Protective Effect of Mesna in Rheumatic Diseases.

  Yilmaz N, Emmungil H, Gucenmez S, Ozen G, Yildiz F, Balkarli A, Kimyon G, Coskun BN, Dogan I, Pamuk ON, Yasar S, Cetin GY, Yazici A, Ergulu Esmen S, Cagatay Y, Yilmaz S, Cefle A, Sayarlioglu M, Kasifoglu T, Karadag O, Pehlivan Y, Dalkilic E, Kisacik B, Cobankara V, Erken E, Direskeneli H, Aksu K, Yavuz S. Yilmaz N, et al. J Rheumatol. 2015 Sep;42(9):1661-6. doi: 10.3899/jrheum.150065. Epub 2015 Jul 15. J Rheumatol. 2015. PMID: 26178288
• Prevention of further cyclophosphamide induced hemorrhagic cystitis by hyperbaric oxygen and mesna in guinea pigs.

  Korkmaz A, Oter S, Deveci S, Goksoy C, Bilgic H. Korkmaz A, et al. J Urol. 2001 Sep;166(3):1119-23. J Urol. 2001. PMID: 11490309
• Position statement of the Brazilian society of Rheumatology on mesna use as a preventive therapy for bladder disease in patients with systemic autoimmune diseases and systemic vasculitis under cyclophosphamide treatment.

  Souza AWS, Dantas JG, Montandon ACOES, Calich AL, Mont' Alverne ARS, Gasparin AA, Bianchi D, Yuki EFN, Sacilotto N, Dos Reis Neto ET, Monticielo OA, Pereira IA. Souza AWS, et al. Adv Rheumatol. 2024 May 21;64(1):41. doi: 10.1186/s42358-024-00380-0. Adv Rheumatol. 2024. PMID: 38773538 Review.
• [Cancer of the bladder after cystitis due to cyclophosphamide. Apropos of a case].

  Dore B, Grange P, Aubert J. Dore B, et al. J Urol (Paris). 1989;95(7):427-31. J Urol (Paris). 1989. PMID: 2687398 Review. French.